Survival and prognostic factors in patients with brain metastasis: Single center experience

Basit Öğe Kaydı
dc.authoridtemelli, oztun/0000-0003-3471-1284
dc.authorwosidtemelli, Oztun/ABE-6986-2020
dc.authorwosidEkici, Kemal/AAF-6505-2022
dc.authorwosidEkici, Kemal/AFJ-9488-2022
dc.contributor.authorEkici, Kemal
dc.contributor.authorTemelli, Oztun
dc.contributor.authorDikilitas, Mustafa
dc.contributor.authorDursun, Ibrahim Halil
dc.contributor.authorKaplan, Nihal Bozdag
dc.contributor.authorKekilli, Ersoy
dc.date.accessioned2024-08-04T20:42:42Z
dc.date.available2024-08-04T20:42:42Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: The purpose of this study was to evaluate the clinical status, prognostic factors and treatment modalities affecting survival in patients with brain metastasis. We aimed to evaluate the whole brain radiation therapy (WBRT) outcomes of patients with brain metastasis in our center. Methods: Clinical data of 315 patients referred to our center between 2004 and 2014 with metastatic brain cancers were collected and analysed for possible relationships between survival time, age, gender, Karnofsky performance status (KPS), recursive partitioning analysis (RPA), primary tumor, number of brain lesions, surgery, radiation therapy scheme, extracranial metastatic status and primary disease control status. Results: The average patient age of onset was 58 years. The primary tumor site was lung (68%), breast (12%), melanoma (4%), colorectal (1.6%), sarcoma (1.3%) and unknown primary disease (4.4%). The rest of the patients had other primary sites. Eighty four (26.6%) patients had single brain metastasis, 71 (22.5%) had 2 or 3 lesions, and 159 (50.4%) patients had more than 3 lesions. Leptomeningeal involvement was seen in combination of paranchymal involvement in 11 (3.5%) patients. Fifty patients had undergone surgical resection. WBRT was delivered to all of the patients. Median overall survival was 6.7 months (95% CI, 5.80-7.74). Median overall survival of patients treated with combination of surgery and WBRT was significantly better compared with those treated with WBRT alone (13.5 vs 5.5 months, p=0.0001). One- and 2- year survival was 17 and 4.7%, respectively. Conclusions: The present study concludes that brain metastasis is common in cancer patients. The best overall survival was obtained by surgery+NBRT in good-condition patients. Treatment should be tailored on an individual basis to all these patients.en_US
dc.identifier.endpage963en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue4en_US
dc.identifier.pmid27685920en_US
dc.identifier.scopus2-s2.0-84991670925en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage958en_US
dc.identifier.urihttps://hdl.handle.net/11616/97537
dc.identifier.volume21en_US
dc.identifier.wosWOS:000383306700026en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Medical Publen_US
dc.relation.ispartofJournal of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbrain metastatic cancersen_US
dc.subjectprognosisen_US
dc.subjectradiotherapyen_US
dc.subjectsurvivalen_US
dc.titleSurvival and prognostic factors in patients with brain metastasis: Single center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu